Investors | Prolira

Prolira is a commercial stage company with a compelling value proposition serving a significant unmet medical need. Fanatical about capital efficiency, Prolira has significantly de-risked the company, achieving clearance in the EU and US, validation and outcome evidence, and a validated workflow integration strategy with $8M in equity funding to date.

The company is currently raising a Series A round to support commercial expansion, additional clinical evidence, and our next-gen patient interface. With this 2-year funding the company is posed for either strategic exit or a series B growth round.

"As many as 30% of cardiac surgery patients will develop postoperative delirium. Postoperative delirium has been associated with increased disability and morbidity, resulting in prolonged in-hospital stay and increased costs. Currently, the diagnosis of delirium is based upon clinical evaluation. Therefore, the diagnosis of delirium is usually delayed, at best, if not completely missed."

"Measurement of processed EEG signals might not only permit early and more sensitive detection of delirium, but also contribute to stratify the risk for this neurological complication before it manifests clinically, offering a unique opportunity for targeted therapies and improvement of clinical outcomes."

Marcelo Gama de Abreu - Cleveland Clinics
Director of Research, Professor of Anesthesiology, Department of Intensive Care and Resuscitation, Department of Outcomes Research, Anesthesiology Institute Cleveland Clinic Foundation Hospital

"In the ICU, delirium is notoriously difficult to diagnose. Time and again patients with a hypoactive delirium remain under our radar. During follow-up interviews, it has repeatedly become evident just how terrifying and unpleasant delirium is for the patient and the effects can persist in someone’s life for years afterwards. We must do everything we can to minimize the consequences of delirium."

Dr. Thomas Ottens, Haga Hospital
Anaesthesiologist-intensivist Haga Hospital, The Hague

The Prolira DeltaScan® Brain State Monitor is a $1.5 Billion+ Market Opportunity for the US and EU

Connect with the Prolira Team